SCM
DNLI icon

SCS Capital Management’s Denali Therapeutics DNLI Stock Holding History

SCS Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.8M Hold
197,998
– – 0.04% 162
2025
Q4 		$3.27M Hold
197,998
– – 0.03% 175
2025
Q3 		$2.87M Hold
197,998
– – 0.03% 184
2025
Q2 		$2.77M Hold
197,998
– – 0.03% 194
2025
Q1 		$2.69M Buy
+197,998
New +$3.79M 0.03% 172

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SCS Capital Management's DNLI Position: Q1 2026 in Review

SCS Capital Management held its Denali Therapeutics (DNLI) position steady in Q1 2026 at 197,998 shares worth $3.8M. The position accounts for 0.04% of the portfolio, ranked #162.

SCS Capital Management first reported a position in DNLI in Q1 2025 and has held it in 5 quarters since. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • SCS Capital Management held 197,998 shares of Denali Therapeutics worth $3.8M as of Q1 2026.
  • SCS Capital Management left its Denali Therapeutics share count unchanged in Q1 2026.
  • Denali Therapeutics made up 0.04% of SCS Capital Management's portfolio in Q1 2026, its #162 holding.
  • SCS Capital Management first reported a position in Denali Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on SCS Capital Management's 13F filing for Q1 2026, filed 11 May 2026.